tibulizumab

Home
Ligands
tibulizumab

GtoPdb Ligand ID: 10350

Synonyms: LY-3090106 | LY3090106

Comment: Tibulizumab (LY3090106) is an investigational bispecific monoclonal antibody. It is a humanized antibody that simultaneously targets IL-17A and BAFF (TNFSF13B; CD257), that was produced by Eli Lilly as a potential therapeutic for IL-17-driven autoimmune diseases. Peptide sequences for tibulizumab (accessed from IMGT) are 100% matches with SEQ IDs 1 and 2 from patent WO2013158577A1, entitled 'Anti-baff-anti-il-17 bispecific antibodies' [1]. Tibulizumab neutralises IL-17 and BAFF bioactivities in vitro and in vivo [1].

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Allan B, Benschop RJ, Lu J. (2013) Anti-baff-anti-il-17 bispecific antibodies. Patent number: WO2013158577A1. Assignee: Eli Lilly. Priority date: 20/04/2012. Publication date: 24/10/2013.

References

1. Allan B, Benschop RJ, Lu J. (2013)
Anti-baff-anti-il-17 bispecific antibodies.
Patent number: WO2013158577A1. Assignee: Eli Lilly. Priority date: 20/04/2012. Publication date: 24/10/2013.